Top 50 Biotechnology Startup Investors in United States (June 2026)

Portfolio highlights

• MixRift — MIXRIFT - game developers specialized in Mixed Reality
• unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
• Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Portfolio highlights

• Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
• EGenesis — At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.
• Protillion Biosciences — Protillion Biosciences is a biotech company commercializing disruptive technology for therapeutic antibody and drug discovery and accelerating biologic research and development productivity.

Portfolio highlights

• miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
• Marvin Health — Marvin is a mental health service for physicians. We're ending the one-size-fits-all approach to teletherapy, helping you to set a teletherapy action plan.
• Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.

Portfolio highlights

• Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
• resTORbio — Restore Beauty - Rethink Bio
• Caris Life Sciences — Caris fulfills the promise of precision oncology through advanced laboratory testing, including tumor profiling and blood-based cancer diagnostics.

Portfolio highlights

• Grockit — Grockit is a pioneering online social learning company. Grockit has proven that people learn more, faster through combining social learning mechanics and multi-media learning content to help people teach and learn from others. Grockit.com offers Test Prep services for GMAT, IIM CAT, LSAT, GRE, ACT, SAT and AP Calculus and AP History tests.Grockit has built a social learning test prep platform for license and direct-to-consumer products. Florida Virtual Schools, KIPP Schools, Georgetown University and other schools have deployed Grockit services.
• Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
• Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.

Portfolio highlights

• AviadoBio — AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK DementiaResearch Institute.
• Sagimet Biosciences — Sagimet Biosciences better reflects our expertise in fatty acid metabolism and current focus on developing ground-breaking therapeutics to treat the liver disease NASH.
• Tarveda Therapeutics — Developing Pentarins to make a difference in the treatment of patients with solid tumor malignancies

Portfolio highlights

• Achaogen — Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrumefficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
• Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
• Dayra Therapeutics —

Portfolio highlights

• Jibe — ICIMS is a leading talent acquisition platform offering AI-powered applicant tracking, candidate engagement, onboarding, employer branding, and career site software to help organizations hire top talent at scale.
• Thirty Madison — Thirty Madison is a human-first healthcare company, powering access to affordable specialized healthcare through brands like Keeps and Cove.
• Hydra Biosciences — Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that addresssignificant unmet medical needs.Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Portfolio highlights

• HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
• Rescue Forensics — Customer service is our #1 priority. Get a premium domain for your website today. Financing available.
• Soiltech Wireless — Soiltech Wireless is a developer of ag-tech solutions to design electronic devices for agricultural professionals. Its product provides real-time data to drive efficiency and optimize quality. It also provides actionable data without installation hassles and creates scalable monitoring solutions for farmers.The company was founded in 2019 and isheadquartered in Rupert, Idaho.

Portfolio highlights

• CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
• Jounce Therapeutics — Concentra is a biosciences company.
• Syremis Therapeutics —

Portfolio highlights

• Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
• Mendra — Mendra is a biopharmaceutical company that uses AI to accelerate clinical development and commercialization of breakthrough medicines for diseases with high unmet need.
• Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.

Portfolio highlights

• Hunch — Hunch is a consumer web application that is building the "taste graph" of the internet, mapping every person on the internet to every entity on the internet and their affinity for that entity. An entity could be a web site, a cookbook, a hotel room, a celebrity, a restaurant, etc.Hunch creates a taste profile by asking them a seriesof questions which range from serious to profound and subsequently can make recommendations personalized to that user, which live in "topics".Topics vary widely, from entertaining subjects like 'Which superhero would you be' to more conventional questions like 'Should I Switch to A Mac?' The system then uses the answers to these questions to offer the user a suggested solution, a "hunch" of what the user would like.
• Speak — People spend $90 billion a year on human english teachers that are expensive and ineffective. Speak offers a mobile app where you can have english conversations with your phone about real world scenarios like interviewing for a job or asking for directions. It uses speech recognition to identify english words through thick accents and teach peopleto speak more clearly. Meanwhile, it’s building a massive database of accented-english speech, which can be used to improve its system and other speech recognition systems. Speak’s team formerly built accent detection systems and sold Flashcards+ to Chegg. Though AI translation might reduce the need for people to know other languages, speaking English remains a valuable skill people are willing to pay for.
• The Climate Corporation (Bayer Crop Science) — The Climate Corporation (formerly WeatherBill) aims to help farmers around the world protect and improve their farming operations with uniquely powerful software, hardware and insurance products. The company’s proprietary Climate Technology Platform combines hyper-local weather monitoring, agronomic modeling, and high-resolution weather simulationsto deliver Climate Basic and Climate Pro, mobile SaaS solutions that helps farmers improve profitability by making better informed operating and financing decisions.

Portfolio highlights

• Epigenomics — Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions ofindividuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.
• Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
• Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Portfolio highlights

• Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
• Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
• ILiAD Biotechnologies —

Portfolio highlights

• SILQ — Bringing visibility to brands by customizing sourcing and shipping on everything that you need for your business.
• Deal Engine — Deal Engine is a travel solutions software company that reduces corporate travel expenditure ensuring saving on a flight itinerary.
• RightHand Robotics — RightHand Robotics offers advanced robotic piece-picking technology for efficient and predictable order fulfillment. Contact us today to learn how.

Portfolio highlights

• Humio — Humio operates as a time-series logging and aggregation platform designed for unrestricted and comprehensive event analysis. It is deployable on any infrastructure including both in the cloud and on-premises. Humio enables data aggregation, exploration, reporting, and analysis from a range of sources ingesting massive volumes of log data instantly.Its data storage and in-memory search/query engine technologies provide customers cost-competitive log management and analysis solution, all while requiring significantly less hardware and engineering resources.The company was founded in 2016 and is headquartered in London, England.
• OpusClip — Opus Clip turns long videos into high-quality viral clips for you to share on TikTok, YouTube Shorts, and Reels to increase social media reach.
• Arda Therapeutics — Arda Therapeutics is a biotechnology company taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions. Their approach starts by using single-cell data to identify pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.Arda wasfounded in 2021 in the San Francisco Bay Area, CA.

Portfolio highlights

• CarTrade — CarTrade - Buy and Sell Used Cars in India at right price. Find New Cars, car prices, upcoming cars and images. Read latest auto news, reviews and car comparisons.
• Matrimony.com — Revolutionizing the Indian matrimonial industry with world class matchmaking and wedding planning services. Your search for the perfect match ends here!
• Savvy — Savvy is a software development company that engages in cybersecurity.

Portfolio highlights

• Latus Bio — Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.
• Tolerance Bio — Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
• Vittoria Biotherapeutics — Vittoria Biotherapeutics develops gene-edited cell therapies.  they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Portfolio highlights

• Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
• Atavistik Bio — Atavistik Bio is harnessing the power of protein-metabolite interactions to add a new lens to drug discovery.
• Peloton Therapeutics — Peloton Therapeutics is translating groundbreaking scientific insights into first-in-class oral medicines to fight cancer and other serious conditions.

Portfolio highlights

• Julep — We are Julep, creators of innovative makeup, skincare, nail polish & sets. Every day is a chance to Brave Pretty.
• Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
• Adaptive Security — Adaptive's next-generation security training and simulations protect businesses from deepfakes, generative AI phishing, SMS attacks, voice phishing, and more emerging threats.

Portfolio highlights

• Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days.
• Checkerspot — A biology-driven platform creating specialized lipids from fermentation
• Tierra Biosciences — Speed, scale and simplicity with protein synthesis on-demand. Discover your portal to thousands of custom proteins. Get testable material with a single input.

Portfolio highlights

• Allara — Allara is your all-in-one virtual care team for hormonal, metabolic & gynecological conditions such as PCOS and Endometriosis.
• Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
• Merida Biosciences — Merida Biosciences is a new biotech company focused on developing precision treatments, particularly for autoimmune diseases. The company utilize a protein engineering platform to create unique Fc therapeutics, aiming to selectively bind to specific antibodies.

Portfolio highlights

• Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
• Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
• Amphista Therapeutics — We are purposefully designing the next generation of targeted protein degraders to transform the lives of patients with intractable diseases.

Portfolio highlights

• Arraiy — Headquartered in Palo Alto, Arraiy is building the premier AI-driven production platform for the motion picture and television industry. Arraiy is collaborating with major studios, industry veterans, and award-winning artists to re-invent the filmmaking process with machine learning at its foundation. With its products, Arraiy seeks to enhance thecreative freedom of storytellers and unlock the next generation of visual storytelling.
• Clarifai — Clarifai is the leading Machine Learning, Computer Vision, NLP Platform. Label, train, deploy models on one AI platform for developers & data scientists.
• Primer — Primer makes powerful mission-ready AI software designed to work in your environment, on your data. We help national security teams sift through massive unstructured data sets to find the needle in the haystack, understand and visualize their data, and act collaboratively. Our mission is to empower decisions that can be defended, and acted upon confidently.

Portfolio highlights

• Twelve — Twelve is a carbon transformation company converting captured carbon dioxide into valuable chemicals, fuels, and other essential products. Their technology eliminates emissions by turning CO2 into essential products that are made from fossil fuels. They specialize in the fields of CO2 electrocatalysis and electrochemical reactor design.
• ZwitterCo — ZwitterCo is revolutionizing water & wastewater treatment with cutting-edge membrane technology, along with providing sustainable, high-efficiency solutions.
• Petra — Petra is a robotics company that can bury utilities in the most difficult and disaster-prone areas on earth.

Portfolio highlights

• Device42 — Device42 sets the standard as the most comprehensive, agentless discovery and dependency mapping solution, spanning from legacy mainframes to cloud containers.
• Mobile Sense — The traditional diagnostic market is being transformed by advances in high performance wearables. This seismic shift led by consumer products which are uncovering new patients who previously went undetected, but still require a detailed diagnosis. Mobile Sense™ is building foundational technology that enables this transformation throughoff-the-chest wearables for long term management of cardiac arrhythmias. Developed over 7 years with $4.2M in grant funding and $1.3M in seed funding, Mobile Sense™ has a platform for differentiated wearables. Our embedded algorithms coupled with non-adhesive, wireless & waterproof sensors provides high fidelity continuous ECG and PPG recordings. The automatic monitoring provides 24/7, 365 days/yr continuous detection and classification of dangerous heart arrhythmias.
• NovaTract Surgical — NovaTract Surgical is a development stage company, intends to develop medical devices to address the rapidly growing field of Single Incision Laparoscopic Surgery (SILS) and Natural Orifice Transluminal Endoscopic Surgery (NOTES). The company was incorporated in 2010 and is based in Guilford, Connecticut.

Portfolio highlights

• Farcast — Unlocking satellite internet capacity through user terminal innovation
• Solugen — Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition.
• Valence Discovery — Empowering drug discovery scientists with the latest advances in AI-enabled drug design

Portfolio highlights

• Lightform — Lightform LFC Kit and LF2+ AR projector enable you to create light and sound experiences with sound-reactive projection mapping. Lightform brings projection mapping in reach for visual artists, designers, and other creatives.
• TripleBlind — TripleBlind unlocks the estimated 105 petabytes of data stored by enterprises today that are inaccessible and not commercialized due to privacy concerns, operational complexity and regulation. The company’s patented breakthroughs in advanced mathematics enable organizations to privately share larger and more diverse data sets. Many high-valueapplications apply, such as innovating enhanced algorithms for medical diagnoses and improving anti-fraud initiatives for financial services. TripleBlind is the only technology that enables enterprises to rapidly commercialize data while maintaining compute performance; enabling all types of analysis on all data types, such as PII, PHI, genomic data, images, and confidential financial records. At the same time, the solution automatically enforces all international and regional data privacy standards including HIPAA, GDPR, PDPA and CCPA.TripleBlind is superior to existing solutions such as homomorphic encryption (slows compute performance), secure enclaves (siloes data), tokenization/masking/hashing and differential privacy (reduces accuracy), synthetic data (not real data), federated learning (limited use for algorithms), confidential computing (requires data centralization) and blockchain (not interoperable). Innovators such as Accenture, the Mayo Clinic and Snowflake trust TripleBlind to protect sensitive data. Please contact us for an overview, live demo or a one-hour, hands-on workshop.
• Cognitive Space — Automating satellite operations and satellite Data-as-a-Service through AI to empower the use of space.

Portfolio highlights

• Deck Bio — Deck Bio develops multi-target T cell engager immunotherapies for solid tumors.
• Beech Biotech — Beech Biotech is utilizing cutting-edge biology to develop innovative therapies for preeclampsia and other pregnancy-related issues. This business extends pregnancy and lessens the effects of premature birth.
• Bullseye Biosciences — Bullseye Biosciences is a therapeutics discovery company revolutionizing drug development through robotics and evolution. Our platform operationalizes cutting-edge directed evolution technology by incorporating automation and Next Generation Sequencing. By targeting challenging drivers of human dise

Portfolio highlights

• Ribometrix — The Next Frontier of Drug Discovery
• Contego Medical — Better Outcomes. Simplified. Neurovascular Peripheral Vascular Neurovascular
• G1 Therapeutics — G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.

Portfolio highlights

• Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
• Radionetics Oncology — Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is poised to capitalize on the increasing demand for novel radiotherapeutics.
• Zavante Therapeutics — Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

Portfolio highlights

• Cebix — Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.
• Invitae — Invitae and Labcorp together offer advanced genetic testing that can be easily integrated into medical practices. Improve patient care with meaningful insights based on DNA.
• XyloCor Therapeutics — XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.

Portfolio highlights

• QbDVision — QbDVision's digital CMC software for pharma & biotech accelerates drug development by transforming dispersed data & knowledge to process intelligence.
• Culture Biosciences — Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditionalapproaches by robotic sample handling and cloud data monitoring and analysis.Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
• Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.

Portfolio highlights

• Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
• Neuronetics — Antidepressant medications don't work for everyone. If drugs haven't worked for you, learn about NeuroStar - safe, effective, lasting TMS therapy for depression.
• Artios Pharma — Artios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class & best-in-class potential.

Portfolio highlights

• OxCan — Enabling curative cancer treatment through early detection
• Wyndly — Retrain your allergies through sublingual (under-the-tongue) treatment plans. Virtual appointments. Treatment delivered. Get started after your first consult with a board-certified doctor for $49.99.
• Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.

Portfolio highlights

• Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
• Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
• Tobira Therapeutics — Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associatedinfectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.

Portfolio highlights

• Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
• Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
• Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

Portfolio highlights

• Neurava — Neurava has developed wearable diagnostics for epilepsy patients including those at risk of SUDEP. The company specializes in the fields of medical device manufacturing, healthcare, and health diagnostics.
• Flyte — Flyte promotes cellular healing in pelvic floor muscles for lasting results. Flyte is fast, proven, safe, pelvic floor therapy for bladder control.
• Trio Pharmaceuticals — Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California.

Portfolio highlights

• Citrea — Bitcoin's First ZK Rollup
• Polymarket — Bet on your beliefs
• Workstream — Workstream is an automated hiring platform that helps companies employing hourly workers. The platform helped Jamba, Chick-fil-A, McDonald's, Dunkin', Applebee's, Auntie Anne's, Cinnabon to increase their bottom line and cost savings.Workstream was founded in 2017 and is headquartered in San Francisco, California, UnitedStates.

Portfolio highlights

• Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
• Aerium Therapeutics — Aerium is building a company dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats.
• Scorpion Therapeutics — We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.

Portfolio highlights

• Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
• Antios Therapeutics — This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
• Fractyl Health — Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.

Portfolio highlights

• Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.
• Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
• Mindset Medical — Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona.

Portfolio highlights

• Epirus — Epirus is a high-growth technology company that develops cutting-edge directed energy systems and power management solutions to transform multiple industries.
• Operant — Own OperantAi.com today. Secure checkout and guided transfer support. No hidden fees.
• Quadient Accounts Receivable by YayPay — YayPay accounts receivable automation software helps businesses collect faster, forecast cash flow accurately, and improve payment process. Automate your AR

Portfolio highlights

• CubaseBio — Cubase Bio is a biotechnology business that focuses on spatial biology tools. It creates solutions for 3D spatial analysis to speed up drug discovery.
• Precede Biosciences — Precede Biosciences is revolutionizing precision medicine by revealing unprecedented insights into disease-defining biology from a simple blood test. Discover how we are helping create a world where medicine is developed more successfully, and every diagnosis is precise and minimally invasive.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Knowde — knowde is the online marketing platform dedicated to chemicals and ingredients. They make it easy to connect with customers, online. Use knowde Pages to get your products noticed every time a customer searches on any search engine. Build your knowde Page in an hour and get started for free.
• Shield Bio — At Shield, we’re ensuring that antibiotic resistance doesn’t become more deadly than cancer.In 2050 more people will be dying of antibiotic resistant pathogens than cancer. Infections that were once treatable with a simple oral antibiotics are now requiring complex, painful treatments and resulting in serious health complications for patients.Gonorrhea is one such infection, having become resistant to over 10 different antibiotics, they have only one treatment that is still effective and resistance to this has already begun to emerge. With 820,000 new infections every year in the US, antibiotic resistance will spread quickly, which is why the CDC has resistant gonorrhea at an urgent threat level, the highest level available.Shield's novel genomic testing platform enables STI clinics to identify the antibiotic resistant strains of gonorrhea and other pathogens that their patients have, so they can select the correct antibiotics and halt the spread of antibiotic resistance.
• Verge Genomics — Verge Genomics has pioneered the industry's most advanced all-in-human AI powered drug discovery platform. Our mission is to develop better drugs, faster using technology.

Portfolio highlights

• Etiome — Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines.
• Quotient Therapeutics — Discover how Quotient is pioneering a new field of genetics with somatic genomics to unveil a universe of genetic information and develop new therapies.
• Ampersand Biomedicines — Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.

Portfolio highlights

• Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
• Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
• Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.

Portfolio highlights

• Phase — Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
• QATCH Technologies — Get the most out of a drop
• Atlantic Fish Company — Atlantic Fish Co is a cultivated seafood company using cellular agriculture to bring the world sustainable delicious seafood.

Portfolio highlights

• Inspirna — Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs arefirst-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2)
• Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
• Rgenta Therapeutics — Our mission is to develop RNA-targeting medicines to treat previously incurable diseases

Portfolio highlights

• Sanegene Bio — Sanegene Bio is currently operating in stealth mode.
• Excelsior Sciences — Excelsior Sciences develops a chemistry and AI platform for discovering and manufacturing small-molecule compounds. It uses a proprietary “smart bloccs” system, which consists of modular, machine-ready chemical building blocks, to convert small-molecule innovation into an iterative, automation-friendly workflow. Through this platform, Excelsiorenables closed-loop cycles of AI-guided synthesis, testing, and optimisation that link early-stage discovery to scalable manufacturing. The company supports projects across pharmaceuticals, materials science, and other sectors that rely on small molecules. Excelsior also maintains an internal pipeline of therapeutic candidates while working with partners to deploy its chemistry platform broadly.
• Syndeio Biosciences — Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders.